



Sistema Integral de Información Académica
Coordinación de Planeación, Evaluación y
Simplificación de la Gestión Institucional
Reporte individual



DAVID KERSHENOBICH STALNIKOWITZ

Datos Generales

Nombre: DAVID KERSHENOBICH STALNIKOWITZ

Máximo nivel de estudios: DOCTORADO

Antigüedad académica en la UNAM: 50 años

Nombramientos

Vigente: PROFESOR ASIGNATURA A No Definitivo
Facultad de Medicina
Desde 16-04-2013


Estímulos, programas, premios y reconocimientos

SNI Emérito 2010 - VIGENTE
SNI III 2008
PRIDE D - 2009
HONORIS CAUSA Doctor Honoris Causa 2015

DAVID KERSHENOBICH STALNIKOWITZ

DOCUMENTOS EN REVISTAS

Histórico de Documentos



#	Título	Autores	Revista	Año
1	Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver Cirrhosis	DAVID KERSHENOBICH STALNIKOWITZ Sanz-García C. Nevzorova Y.A. et al.	GASTROENTERO LOGIA Y HEPATOLOGIA	2023
2	Outcomes in Temporary ICUs Versus Conventional ICUs: An Observational Cohort of Mechanically Ventilated Patients With COVID-19-Induced Acute Respiratory Distress Syndrome	LUIS ALBERTO MORALES PAREDES ALFREDO PONCE DE LEON GARDUÑO JOSE ANGEL BALTAZAR TORRES et al.	Critical Care Explorations	2022
3	Liver transplantation is beneficial regardless of cirrhosis stage or acute-on-chronic liver failure grade: A single-center experience	DAVID KERSHENOBICH STALNIKOWITZ ALDO TORRE DELGADILLO Cervantes-Alvarez E. et al.	WORLD JOURNAL OF GASTROENTERO LOGY	2022
4	Prevalence of hepatitis C in the adult Mexican population: National Survey of Health and Nutrition 2018	MARTIN ROMERO MARTINEZ DAVID KERSHENOBICH STALNIKOWITZ CELIA MERCEDES ALPUCHE ARANDA et al.	LANCET REGIONAL HEALTH-AMERIC AS	2022
5	Probability of hospitalisation and death among COVID-19 patients with comorbidity during outbreaks occurring in Mexico City	JOSE SIFUENTES OSORNIO GUILLERMO DE ANDA JAUREGUI ENRIQUE HERNANDEZ LEMUS et al.	JOURNAL OF GLOBAL HEALTH	2022

DAVID KERSHENOBICH STALNIKOWITZ

6	Erratum: In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation (PLOS ONE 16(2) (e0245772) DOI: 10.1371/journal.pone.0245772)	EDGAR ORTIZ BRIZUELA THIERRY HERNANDEZ GILSOUL ALFONSO GULIAS HERRERO et al.	PLOS ONE	2022
7	NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study	EDGAR ORTIZ BRIZUELA MONICA CHAPA IBARGUENGOITIA JOSE SIFUENTES OSORNIO et al.	INTERN EMERG MED	2022
8	Galectin-3 is overexpressed in advanced cirrhosis and predicts post-liver transplant infectious complications	JUAN CARLOS PEREZ MONTER ARMANDO GAMBOA DOMINGUEZ CARLOS ALBERTO AGUILAR SALINAS et al.	LIVER INTERNATIONAL	2022
9	Micro-elimination of Hepatitis C in Low- and Middle-Income Settings: Challenges and Windows of Opportunity	DAVID KERSHENOBICH STALNIKOWITZ Wolpert Barraza E. Guerrero Guerrero J.E. et al.	Clinical Liver Disease	2022
10	Large scale screening for SARS-CoV-2 among healthcare workers: Prevalence and risk factors for asymptomatic/pauci-symptomatic carriers, with emphasis on PPE use	EDGAR ORTIZ BRIZUELA DAVID KERSHENOBICH STALNIKOWITZ GUILLERMO MIGUEL RUIZ PALACIOS Y SANTOS et al.	INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY	2022
11	In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation	EDGAR ORTIZ BRIZUELA ARTURO GALINDO FRAGA DAVID KERSHENOBICH STALNIKOWITZ et al.	PLOS ONE	2021
12	The case for simplifying and using absolute targets for viral hepatitis elimination goals	DAVID KERSHENOBICH STALNIKOWITZ Homie Razavi Sarah Blach et al.	JOURNAL OF VIRAL HEPATITIS	2021
13	Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients	JOSE LUIS PEREZ HERNANDEZ EDUARDO ESTEBAN MONTALVO JAVE DAVID KERSHENOBICH STALNIKOWITZ et al.	World Journal of Hepatology	2021
14	Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B	MARIA DE FATIMA HIGUERA DE LA TIJERA ROSALBA MORENO ALCANTAR MAURICIO CASTILLO BARRADAS et al.	REVISTA DE GASTROENTERO LOGIA DE MEXICO	2021
15	Eliminating Hepatitis C in Mexico: A Primary Health Care Approach	DAVID KERSHENOBICH STALNIKOWITZ ALEJANDRO ERNESTO SVARCH PEREZ HUGO LOPEZ GATELL RAMIREZ et al.	Clinical Liver Disease	2021
16	Prevalence and predictors of elevated liver enzyme levels in Mexico: The Mexican National Health and Nutrition Survey, 2016	CARLOS ALBERTO AGUILAR SALINAS DAVID KERSHENOBICH STALNIKOWITZ Denova-Gutiérrez E. et al.	Annals Of Hepatology	2021

DAVID KERSHENOBICH STALNIKOWITZ

17	Cost-effectiveness of a self-management and comprehensive training intervention in patients with type 2 diabetes up to 5 years of diagnosis in a specialized hospital in Mexico City	LUIS ARTURO SANCHEZ TRUJILLO ENRIQUE OCTAVIO GRAUE HERNANDEZ CARLOS ALBERTO AGUILAR SALINAS et al.	BMJ OPEN DIABETES RESEARCH & CARE	2021
18	Plasma ccl16 chemokine secretion and expression in liver tissue of patients with autoimmune hepatitis: A pilot study	DAVID KERSHENOBICH STALNIKOWITZ Romano-Munive A.F. Moctezuma-Velázquez C. et al.	Acta Gastroenterolo gica Latinoamerican a	2021
19	Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City	EDGAR ORTIZ BRIZUELA ALFONSO GULIAS HERRERO DAVID KERSHENOBICH STALNIKOWITZ et al.	FRONTIERS IN PHARMACOLOG Y	2021
20	The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City	Alberto Cedro Tanda GUILLERMO DE ANDA JAUREGUI ROSAURA RUIZ GUTIERREZ et al.	Viruses-Basel	2021
21	Erratum: CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH COVID-19 IN A TERTIARY CARE CENTER IN MEXICO CITY: A PROSPECTIVE COHORT STUDY (Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion (2020) 72 3 (165-177))	EDGAR ORTIZ BRIZUELA THIERRY HERNANDEZ GILSOUL JOSE GUILLERMO DOMINGUEZ CHERIT et al.	REVISTA DE INVESTIGACION CLINICA-CLINIC AL AND TRANSLATIONAL INVESTIGATION	2020
22	Submuestra para el análisis de enfermedades crónicas con biomarcadores, Encuesta Nacional de Salud y Nutrición 2016	MARTIN ROMERO MARTINEZ JAVIER SEPULVEDA AMOR CARLOS ALBERTO AGUILAR SALINAS et al.	SALUD PUBLICA DE MEXICO	2020
23	Prevalence and associated risk factors of diabetic retinopathy and macular oedema in patients recently diagnosed with type 2 diabetes	ENRIQUE OCTAVIO GRAUE HERNANDEZ CARLOS ALBERTO AGUILAR SALINAS DAVID KERSHENOBICH STALNIKOWITZ et al.	Bmj Open Ophthalmology	2020
24	Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C	EDUARDO ESTEBAN MONTALVO JAVE JOSE LUIS PEREZ HERNANDEZ MARIA DE FATIMA HIGUERA DE LA TIJERA et al.	REVISTA DE GASTROENTERO LOGIA DE MEXICO	2020

DAVID KERSHENOBICH STALNIKOWITZ

25	Development and Validation of a Software Linked to an Internet Portal That Facilitates the Medical Treatment and Empowerment of Patients with Type 2 Diabetes, Interaction with Medical Personnel, and the Generation of a Real-Time Registry	CARLOS ALBERTO AGUILAR SALINAS HECTOR RAFAEL VELAZQUEZ JURADO DAVID KERSHENOBICH STALNIKOWITZ et al.	Journal of diabetes science and technology	2020
26	Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients	DAVID KERSHENOBICH STALNIKOWITZ Maria J. Lizardo-Thiebaud Eduardo Cervantes-Alvarez et al.	SEMINARS IN LIVER DISEASE	2020
27	Translation of gastric disease progression at gene level expression	CLAUDIA IVETTE RIVAS ORTIZ SERGIO PONCE DE LEON ROSALES ARMANDO GAMBOA DOMINGUEZ et al.	JOURNAL OF CANCER	2020
28	Differential production of insulin-like growth factor-binding proteins in liver fibrosis progression	JOSE LUIS PEREZ HERNANDEZ EDUARDO ESTEBAN MONTALVO JAVE ALDO TORRE DELGADILLO et al.	MOLECULAR AND CELLULAR BIOCHEMISTRY	2020
29	The Mexican consensus on alcoholic hepatitis	MARIA DE FATIMA HIGUERA DE LA TIJERA DAVID KERSHENOBICH STALNIKOWITZ ROSALBA MORENO ALCANTAR et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	2020
30	CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH COVID-19 IN A TERTIARY CARE CENTER IN MEXICO CITY: A PROSPECTIVE COHORT STUDY	EDGAR ORTIZ BRIZUELA THIERRY HERNANDEZ GILSOUL EDUARDO RIVERO SIGARROA et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2020
31	DILEMMAS OF A PHYSICIAN IN TIMES OF COVID-19	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2020
32	Overweight and obesity status from the prenatal period to adolescence and its association with non-alcoholic fatty liver disease in young adults: cohort study	ERNESTO ALEJANDRO ROLDAN VALADEZ DAVID KERSHENOBICH STALNIKOWITZ HAILIN ZHAO HU et al.	BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY	2020
33	Young adult binge drinkers have immunophenotypical disarrangements in peripheral natural killer cells	ROSA MARIA QUISPE SICCHA JOSE LUIS ZALDIVAR FUJIGAKI DAVID KERSHENOBICH STALNIKOWITZ et al.	Alcohol	2019

DAVID KERSHENOBICH STALNIKOWITZ

34	Prolactin induces il-2 associated trail expression on natural killer cells from chronic hepatitis c patients in vivo and in vitro	MARIA LUISA HERNANDEZ MEDEL ESPERANZA GABRIELA GUTIERREZ REYES ARTURO REDING BERNAL et al.	ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS	2019
35	The Mexican consensus on nonalcoholic fatty liver disease	MARIA SARAI GONZALEZ HUEZO NORBERTO CARLOS CHAVEZ TAPIA CARLOS ALBERTO AGUILAR SALINAS et al.	REVISTA DE GASTROENTERO LOGIA DE MEXICO	2019
36	Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells	CRUZ VARGAS DE LEON JULIO CESAR CARRERO SANCHEZ GLORIA EUGENIA QUEIPO GARCIA et al.	PATHOLOGY & ONCOLOGY RESEARCH	2019
37	Acciones prioritarias para un programa nacional de detección, tratamiento y seguimiento de pacientes con hepatitis C	ONOFRE MUÑOZ HERNANDEZ DAVID KERSHENOBICH STALNIKOWITZ Wolpert-Barraza E. et al.	SALUD PUBLICA DE MEXICO	2019
38	Long-term effectiveness of a type 2 diabetes comprehensive care program. The CAIPaDi model	OMAR YAXMEHEN BELLO CHAVOLLA CARLOS ALBERTO AGUILAR SALINAS DAVID KERSHENOBICH STALNIKOWITZ et al.	DIABETES RESEARCH AND CLINICAL PRACTICE	2019
39	Correction: Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico (PLOS ONE (2018) 13: 11(e0207203) Doi : 10.1371/journal.pone.0207203)	PABLO FRANCISCO BELAUNZARAN ZAMUDIO ALFONSO GULIAS HERRERO DAVID KERSHENOBICH STALNIKOWITZ et al.	PLOS ONE	2018
40	The Mexican consensus on the treatment of hepatitis C	MAURICIO CASTILLO BARRADAS NORBERTO CARLOS CHAVEZ TAPIA MARGARITA BEATRIZ DEHESA VIOLANTE et al.	REVISTA DE GASTROENTERO LOGIA DE MEXICO	2018
41	A front-of-pack labelling system for food and beverages for Mexico: a strategy of healthy decision-making	SOPHIA EUGENIA MARTINEZ VAZQUEZ MARIO ENRIQUE ROJAS RUSSELL LAURA MARIA ANTONIETA MORENO ALTAMIRANO et al.	SALUD PUBLICA DE MEXICO	2018
42	Collaborative research and actions on both sides of the US-Mexico border to counteract type 2 diabetes in people of Mexican origin	CARLOS ALBERTO AGUILAR SALINAS DAVID KERSHENOBICH STALNIKOWITZ Barquera S. et al.	GLOBALIZATION AND HEALTH	2018
43	Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico	PABLO FRANCISCO BELAUNZARAN ZAMUDIO ALFONSO GULIAS HERRERO DAVID KERSHENOBICH STALNIKOWITZ et al.	PLOS ONE	2018

DAVID KERSHENOBICH STALNIKOWITZ

44	Presentación	DAVID KERSHENOBICH STALNIKOWITZ Shamah-Levy T.	SALUD PUBLICA DE MEXICO	2018
45	Heading toward the elimination of hepatitis c virus	DAVID KERSHENOBICH STALNIKOWITZ Torre-Delgadillo A. Aguilar-Valenzuela L.M.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2018
46	Young adult binge drinkers have immunophenotypic changes in peripheral polymorphonuclear cells and monocytes	ALFONSO GASTELUM STROZZI DAVID KERSHENOBICH STALNIKOWITZ Pérez-García, A. et al.	AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE	2018
47	NutriNet-Salud Mexico. Prospective study online: 2018-2028. Relationship between nutrition and health and determinants of dietary habits and nutritional status	DAVID KERSHENOBICH STALNIKOWITZ PABLO ANTONIO KURI MORALES Jorge Armando Barriguet-Melendez et al.	CIRUGIA Y CIRUJANOS	2018
48	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study	DAVID KERSHENOBICH STALNIKOWITZ NAHUM MENDEZ SANCHEZ Razavi-Shearer D. et al.	LANCET GASTROENTEROLOGY & HEPATOLOGY	2018
49	Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach	ALDO TORRE DELGADILLO DAVID KERSHENOBICH STALNIKOWITZ Jiménez, J.V. et al.	DIGESTIVE DISEASES AND SCIENCES	2017
50	Lactancia materna en México	DAVID KERSHENOBICH STALNIKOWITZ	SALUD PUBLICA DE MEXICO	2017
51	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study	DAVID KERSHENOBICH STALNIKOWITZ NAHUM MENDEZ SANCHEZ Blach, S. et al.	LANCET GASTROENTEROLOGY & HEPATOLOGY	2017
52	Fibrosis evaluation of animal liver tissue by thermal conduction	ENOC GUTIERREZ HERRERA DAVID KERSHENOBICH STALNIKOWITZ CELIA ANGELINA SANCHEZ PEREZ et al.	IFMBE Proceedings	2017
53	NutriNet Health Mexico France 2017-2027: Prospective Internet Study. Prevention Digital Network	DAVID KERSHENOBICH STALNIKOWITZ PABLO ANTONIO KURI MORALES JUAN JULIO MORALES CONTRERAS et al.	E-Memoires De L Academie Nationale De Chirurgie	2017
54	Evaluation of liver fibrosis using Raman spectroscopy and infrared thermography: A pilot study	DAVID KERSHENOBICH STALNIKOWITZ Ramírez-Elías, M.G. Kolosovas-Machuca, E.S. et al.	PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY	2017

DAVID KERSHENOBICH STALNIKOWITZ

55	High HPgV replication is associated with improved surrogate markers of HIV progression	DAVID KERSHENOBICH STALNIKOWITZ MARTHA PATRICIA OSTROSKY SHEJET GUILLERMO MIGUEL RUIZ PALACIOS Y SANTOS et al.	PLOS ONE	2017
56	The expression of PNPLA3 polymorphism could be the key for severe liver disease in NAFLD in hispanic population	LUIS ARTEMIO MARTINEZ VAZQUEZ MARIA ELENA LARRIETA CARRASCO JUAN JOSE CALVA MERCADO et al.	Annals Of Hepatology	2017
57	Los criterios de elegibilidad actuales del Seguro Popular para recibir tratamiento para el virus de la hepatitis C	DAVID KERSHENOBICH STALNIKOWITZ Moctezuma-Velázquez C. Sánchez-Ávila J.F. et al.	SALUD PUBLICA DE MEXICO	2016
58	Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting	MARGARITA BEATRIZ DEHESA VIOLANTE DAVID KERSHENOBICH STALNIKOWITZ Chirino-Sprung, R.A. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2016
59	Behavior of Oxidative Stress Markers in Alcoholic Liver Cirrhosis Patients	YADIRA LILIAN BEJAR RAMIREZ JOSE LUIS PEREZ HERNANDEZ DAVID KERSHENOBICH STALNIKOWITZ et al.	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY	2016
60	Alterations in Activation, Cytotoxic Capacity and Trafficking Profile of Peripheral CD8 T Cells in Young Adult Binge Drinkers	JOSE LUIS ZALDIVAR FUJIGAKI ESPERANZA GABRIELA GUTIERREZ REYES DAVID KERSHENOBICH STALNIKOWITZ et al.	PLOS ONE	2015
61	Regulation on palliative care and assisted suicide [Regulación de los cuidados paliativos y muerte asistida]	DAVID KERSHENOBICH STALNIKOWITZ Cossío-Díaz J.R. González-Salas J.F.F. et al.	GACETA MEDICA DE MEXICO	2015
62	Rapid prototyping of integrated biochips for on-demand 3D cell culture	MATHIEU CHRISTIAN ANNE HAUTEFEUILLE CATALINA ELIZABETH STERN FORGACH JEHU LOPEZ APARICIO et al.	Progress in Biomedical Optics and Imaging	2015
63	The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2	DAVID KERSHENOBICH STALNIKOWITZ NAHUM MENDEZ SANCHEZ Hatzakis A. et al.	JOURNAL OF VIRAL HEPATITIS	2015
64	Historical epidemiology of hepatitis C virus (HCV) in select countries - Volume 2	DAVID KERSHENOBICH STALNIKOWITZ NAHUM MENDEZ SANCHEZ Saraswat V. et al.	JOURNAL OF VIRAL HEPATITIS	2015
65	Strategies to manage hepatitis C virus (HCV) infection disease burden - Volume 2	DAVID KERSHENOBICH STALNIKOWITZ NAHUM MENDEZ SANCHEZ Gane E. et al.	JOURNAL OF VIRAL HEPATITIS	2015

DAVID KERSHENOBICH STALNIKOWITZ

66	Editorial	DAVID KERSHENOBICH STALNIKOWITZ GUILLERMO MIGUEL RUIZ PALACIOS Y SANTOS ALFREDO ANTONIO ULLOA Y AGUIRRE et al.	REVISTA DE INVESTIGACION CLINICA-CLINIC AL AND TRANSLATIONAL INVESTIGATION	2015
67	Hepatitis C screening in the general population	DAVID KERSHENOBICH STALNIKOWITZ Corona-Lau C. Muñoz L. et al.	REVISTA DE INVESTIGACION CLINICA-CLINIC AL AND TRANSLATIONAL INVESTIGATION	2015
68	CARBONYLATED PROTEINS AND GLUTATHIONE LEVELS AS IMPORTANT OXIDATIVE BIOMARKERS IN ALCOHOLIC LIVER DISEASE	DAVID KERSHENOBICH STALNIKOWITZ ESPERANZA GABRIELA GUTIERREZ REYES M. Galicia et al.	JOURNAL OF HEPATOLOGY	2014
69	Innovative models for the empowerment of patients with type 2 diabetes: The CAIPaDi program	CARLOS ALBERTO AGUILAR SALINAS DAVID KERSHENOBICH STALNIKOWITZ Hernández-Jiménez S. et al.	Recent Patents on Endocrine, Metabolic and Immune Drug Discovery	2014
70	Vicissitudes of hepatitis C in Mexico [Vicisitudes de la hepatitis C en México]	DAVID KERSHENOBICH STALNIKOWITZ Aguilar-Valenzuela L.M. Muñoz L.	REVISTA DE INVESTIGACION CLINICA-CLINIC AL AND TRANSLATIONAL INVESTIGATION	2014
71	Acetaldehyde targets superoxide dismutase 2 in liver cancer cells inducing transient enzyme impairment and a rapid transcriptional recovery	DAVID KERSHENOBICH STALNIKOWITZ Clavijo-Cornejo, Denise Gutierrez-Carrera, Mario et al.	FOOD AND CHEMICAL TOXICOLOGY	2014
72	Unfolded protein response activation in cataracts	DAVID KERSHENOBICH STALNIKOWITZ Torres-Bernal, Beatriz E. Fernando Torres-Bernal, Luis et al.	JOURNAL OF CATARACT AND REFRACTIVE SURGERY	2014
73	[Vicissitudes of hepatitis C in México] [Vicisitudes de la hepatitis C en México]	DAVID KERSHENOBICH STALNIKOWITZ Aguilar-Valenzuela L.M. Muñoz L.	REVISTA DE INVESTIGACION CLINICA-CLINIC AL AND TRANSLATIONAL INVESTIGATION	2014

DAVID KERSHENOBICH STALNIKOWITZ

74	Over-expression of human cystatin C in pterygium versus healthy conjunctiva	DAVID KERSHENOBICH STALNIKOWITZ Fernando Barba-Gallardo, Luis Ventura-Juarez, Javier et al.	BMC OPHTHALMOLOGY	2013
75	Liver exhibits thermal variations according to the stage of fibrosis progression: A novel use of modulated-differential scanning calorimetry for research in hepatology	Galileo Escobedo JOSE LUIS ARJONA ROMAN ROSALIA MELENDEZ PEREZ et al.	HEPATOLOGY RESEARCH	2013
76	THE SPANISH-LATIN AMERICAN DILI NETWORK: PRELIMINARY RESULTS FROM A COLLABORATIVE STRATEGIC INITIATIVE	DAVID KERSHENOBICH STALNIKOWITZ Bessone, F. Hernandez, N. et al.	JOURNAL OF HEPATOLOGY	2013
77	THE LIVER EXHIBITS THERMAL VARIATIONS DEPENDING ON THE FIBROSIS DEGREE: A PROOF OF CONCEPT CONCERNING THE USE OF DIFFERENTIAL SCANNING CALORIMETRY FOR ASSESSING LIVER FIBROSIS	JOSE LUIS ARJONA ROMAN ROSALIA MELENDEZ PEREZ ESPERANZA GABRIELA GUTIERREZ REYES et al.	JOURNAL OF HEPATOLOGY	2013
78	Development of medical specialties in Mexico. Department of Health, UNAM, National Academy of Medicine [Desarrollo de las especialidades médicas en México Secretaría de Salud, UNAM, Academia Nacional de Medicina]	ENRIQUE LUIS GRAUE WIECHERS DAVID KERSHENOBICH STALNIKOWITZ ALBERTO LIFSHITZ Y GUINZBERG et al.	Medicina Interna De México	2013
79	Hacia la cobertura universal en salud: Protección social para todos en México	DAVID KERSHENOBICH STALNIKOWITZ Knaut F.M. González-Pier E. et al.	SALUD PUBLICA DE MEXICO	2013
80	Guideline for interpretation and report of the antibody to hepatitis C virus [Guía de interpretación y reporte del anticuerpo a hepatitis C]	DAVID KERSHENOBICH STALNIKOWITZ VICTOR MARCIAL GRANADOS GARCIA Contreras A.M. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2012
81	[Hepatic fibrosis] [Fibrosis hepática]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	2012
82	Building a Spanish-Latin American network on drug induced liver injury: much to get from a joint collaborative initiative	DAVID KERSHENOBICH STALNIKOWITZ NAHUM MENDEZ SANCHEZ Bessone, Fernando et al.	Annals Of Hepatology	2012
83	Cost-Effectiveness of Truncated Therapy for Hepatitis C Based on Rapid Virologic Response	DAVID KERSHENOBICH STALNIKOWITZ Gellad, Ziad F. Muir, Andrew J. et al.	VALUE IN HEALTH	2012

DAVID KERSHENOBICH STALNIKOWITZ

84	The quest for universal health coverage: achieving social protection for all in Mexico	DAVID KERSHENOBICH STALNIKOWITZ Marie Knaul, Felicia Gonzalez-Pier, Eduardo et al.	Lancet	2012
85	In vivo assessment of liver fibrosis using diffuse reflectance and fluorescence spectroscopy: A proof of concept	CAROLINA GUZMAN ARRIAGA JESUS AGUIRRE GARCIA DAVID KERSHENOBICH STALNIKOWITZ et al.	PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY	2012
86	Management of Alcoholic Liver Disease: An Update	DAVID KERSHENOBICH STALNIKOWITZ Dana Lau Corona Ruben Kershenovich et al.	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH	2011
87	CELLULAR SENESENCE IN A MODEL OF EXPERIMENTAL FIBROSIS: DETERMINATION OF TELOMERE LENGTH RECOVERY AND TELOMERASE REACTIVATION	Alains Cequera Karla Senties Navarro Sofia M. Murga Garrido et al.	Hepatology	2011
88	ASSOCIATION OF GENETIC POLYMORPHISMS OF ADH1B, ALDH2 AND CYP2E1 WITH ALCOHOLISM IN A GROUP OF MEXICAN MESTIZOS	ESPERANZA GABRIELA GUTIERREZ REYES Dorothy Rosique Libia E. Corona Caloca et al.	Hepatology	2011
89	Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus	ESPERANZA GABRIELA GUTIERREZ REYES DAVID KERSHENOBICH STALNIKOWITZ Hevezi, Peter A. et al.	Autoimmunity	2011
90	Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients	DAVID KERSHENOBICH STALNIKOWITZ Munoz-Espinosa, Linda Alarcon, Gabriela et al.	Autoimmunity	2011
91	The impact of genetic variability on liver disease in the Hispanic/Latin-American population	Dana Lau Corona DAVID KERSHENOBICH STALNIKOWITZ ESPERANZA GABRIELA GUTIERREZ REYES	Autoimmunity	2011
92	An international consensus for medical leadership on alcohol	DAVID KERSHENOBICH STALNIKOWITZ Coltart, Cordelia Anderson, Ian et al.	Lancet	2011
93	Th2-Associated Alternative Kupffer Cell Activation Promotes Liver Fibrosis without Inducing Local Inflammation	ESPIRIDION RAMOS MARTINEZ JESUS AGUIRRE GARCIA YADIRA LEDESMA SOTO et al.	INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES	2011
94	Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data	DAVID KERSHENOBICH STALNIKOWITZ Razavi, Homie A. Cooper, Curtis L. et al.	LIVER INTERNATIONAL	2011
95	Trends and projections of hepatitis C virus epidemiology in Latin America	DAVID KERSHENOBICH STALNIKOWITZ Razavi, Homie A. Francisco Sanchez-Avila, Juan et al.	LIVER INTERNATIONAL	2011

DAVID KERSHENOBICH STALNIKOWITZ

96	[Institutional strengthening and updating of the National Academy of Medicine of Mexico (results and instrumentalization 2010-2012)]. [Fortalecimiento y modernización institucional de la Academia Nacional de Medicina de México (Resultados	DAVID KERSHENOBICH STALNIKOWITZ PABLO ANTONIO KURI MORALES Ruíz de Chávez M.H. et al.	GACETA MEDICA DE MEXICO	2011
97	Institutional strengthening and modernization of the National Academy of Medicine of Mexico (Results and instrumentation 2010-2012) [Fortalecimiento y modernización institucional de la Academia Nacional de Medicina de México (Resultados e	DAVID KERSHENOBICH STALNIKOWITZ de Chávez M.H.R. Olivares A.M. et al.	GACETA MEDICA DE MEXICO	2011
98	New era of the Gaceta Médica de Mexico [Nueva época de la gaceta médica de México]	DAVID KERSHENOBICH STALNIKOWITZ Ruíz de Chávez M.H.	GACETA MEDICA DE MEXICO	2010
99	Applying DNA computing to diagnose-and-interfere hepatic fibrosis	RICARDO STRAUZ SANTIAGO DAVID KERSHENOBICH STALNIKOWITZ Farfan B. et al.	Proceedings - 2010 6th International Conference On Natural Computation, Icnc 2010	2010
100	Latin American association for the study of the liver practice guidelines on Diagnosis, management, and treatment of hepatitis C	DAVID KERSHENOBICH STALNIKOWITZ Méndez-Sánchez N. Gadano A. et al.	Annals Of Hepatology	2010
101	Variant in PNPLA3 is associated with alcoholic liver disease	DAVID KERSHENOBICH STALNIKOWITZ Tian, Chao Stokowski, Renee P. et al.	NATURE GENETICS	2010
102	Cellular Senescence in Livers from Children with End Stage Liver Disease	ESPERANZA GABRIELA GUTIERREZ REYES MARIA DEL CARMEN GARCIA DE LEON MENDEZ RUY ALONSO PEREZ TAMAYO et al.	PLOS ONE	2010
103	Treatment of HCV infected patients and renal disease	DAVID KERSHENOBICH STALNIKOWITZ	Annals Of Hepatology	2010
104	Proceed With Caution Peginterferon Alpha-2a Versus Peginterferon Alfa-2b in Chronic Hepatitis C. A Systematic Review of Randomized Trials	DAVID KERSHENOBICH STALNIKOWITZ Munoz, Linda Male, Rene et al.	Hepatology	2010

DAVID KERSHENOBICH STALNIKOWITZ

105	ANALYSIS OF GENETIC VARIATION IN GENES ASSOCIATED WITH LIVER DISEASE IN THE MEXICAN POPULATION	Dana Lau Corona ESPERANZA GABRIELA GUTIERREZ REYES DAVID KERSHENOBICH STALNIKOWITZ et al.	Hepatology	2010
106	INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1 LEVELS IN CHRONIC HEPATITIS C PATIENTS	CAROLINA GUZMAN ARRIAGA Ruben Kershenovich DAVID KERSHENOBICH STALNIKOWITZ et al.	Hepatology	2010
107	[AASLD plenary sessions. Liver fibrosis in the plenary sessions of the AASLD-AGA 2010] [Plenarias AASLD: La fibrosis en las sesiones plenarias de la AASLD en la reunión de la AGA 2010]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTERO LOGIA DE MEXICO	2010
108	Effective use of FibroTest to generate decision trees in hepatitis C	Dana Lau Corona LUIS ALBERTO PINEDA CORTES HECTOR HUGO AVILES ARRIAGA et al.	WORLD JOURNAL OF GASTROENTERO LOGY	2009
109	Hepatocyte growth factor protects hepatocytes against oxidative injury induced by ethanol metabolism	DAVID KERSHENOBICH STALNIKOWITZ Valdes-Arzate, Argelia Luna, Armando et al.	FREE RADICAL BIOLOGY AND MEDICINE	2009
110	Acetaldehyde-induced mitochondrial dysfunction sensitizes hepatocytes to oxidative damage	OSCAR FLORES HERRERA DAVID KERSHENOBICH STALNIKOWITZ Farfan Labonne, Blanca Eugenia et al.	CELL BIOL TOXICOL	2009
111	Modification of sleep architecture in an animal model of experimental cirrhosis	DAVID KERSHENOBICH STALNIKOWITZ Jimenez-Anguiano, Anabel Diaz-Medina, Vanessa et al.	WORLD JOURNAL OF GASTROENTERO LOGY	2009
112	Deleterious effects of ethanol metabolism are prevented by HGF-induced activation of NFkB and PI3K/AKT signaling pathways	DAVID KERSHENOBICH STALNIKOWITZ Valdes-Arzate, A Gomez-Quiroz, LE et al.	ALCOHOLISM-C LINICAL AND EXPERIMENTAL RESEARCH	2008
113	Pentoxifylline downregulates alpha (I) collagen expression by the inhibition of I kappa b alpha degradation in liver stellate cells	DAVID KERSHENOBICH STALNIKOWITZ Hernandez, E. Bucio, L. et al.	CELL BIOL TOXICOL	2008
114	THE POSSIBLE ROLE OF PROLACTIN ON INNATE IMMUNE RESPONSE IN CHRONIC HEPATITIS C	ESPERANZA GABRIELA GUTIERREZ REYES Jacqueline Cordova BLANCA EUGENIA FARFAN LABONNE et al.	Hepatology	2008
115	EFFECTIVE USE OF FIBROTEST ATTRIBUTES TO GENERATE DECISION TREES IN HEPATITIS C	Dana Lou Corona LUIS ALBERTO PINEDA CORTES Hector H. Aviles et al.	Hepatology	2008

DAVID KERSHENOBICH STALNIKOWITZ

116	Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders	DAVID KERSHENOBICH STALNIKOWITZ Poo, Jorge L. Sanchez Avila, Francisco et al.	Annals Of Hepatology	2008
117	Preface	DAVID KERSHENOBICH STALNIKOWITZ Martin P.	Archives Of Medical Research	2007
118	Liver Fibrosis and Chronic Viral Hepatitis	ESPERANZA GABRIELA GUTIERREZ REYES DAVID KERSHENOBICH STALNIKOWITZ Gutierrez-Ruiz M.C.	Archives Of Medical Research	2007
119	Seroprevalence of hepatitis C among Mexican adults: An emerging public health problem? [Seroprevalencia de la hepatitis C en adultos de México: ¿Un problema de salud pública emergente?]	DAVID KERSHENOBICH STALNIKOWITZ Valdespino J.L. Conde-González C.J. et al.	SALUD PUBLICA DE MEXICO	2007
120	Prevalence of hepatitis C virus genotypes in Mexican patients.	DAVID KERSHENOBICH STALNIKOWITZ Dehesa-Violante M. Bosques-Padilla F.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	2007
121	Ventricular dysfunction in patients with hepatic cirrhosis [Disfunción ventricular en pacientes con cirrosis hepática]	ALDO TORRE DELGADILLO JOSE ISIDRO ARTURO OREA TEJEDA DAVID KERSHENOBICH STALNIKOWITZ et al.	Medicina Interna De México	2006
122	Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C	ESPERANZA GABRIELA GUTIERREZ REYES DAVID KERSHENOBICH STALNIKOWITZ Lopez-Ortal P. et al.	SCANDINAVIAN JOURNAL OF IMMUNOLOGY	2006
123	Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis	OSCAR GERARDO ARRIETA RODRIGUEZ DAVID KERSHENOBICH STALNIKOWITZ EUCARIO LEON RODRIGUEZ et al.	CANCER	2006
124	Association of alcohol-metabolizing genes with alcoholism in a Mexican Indian (Otomi) population	IVAN PEREZ DIAZ DAVID KERSHENOBICH STALNIKOWITZ Montano Loza A.J. et al.	Alcohol	2006
125	Indications and contraindications for treatment of hepatitis C virus infections	DAVID KERSHENOBICH STALNIKOWITZ	Annals Of Hepatology	2006
126	Myth and realities of antifibrotic medication [Mitos y realidades de los medicamentos antifibróticos.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	2005
127	Differential effect of interleukin-10 on hepatocyte apoptosis	DAVID KERSHENOBICH STALNIKOWITZ Santiago-Lomelí M. Gómez-Quiroz L.E. et al.	LIFE SCIENCES	2005

DAVID KERSHENOBICH STALNIKOWITZ

128	Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon α-2b and ribavirin	ESPERANZA GABRIELA GUTIERREZ REYES DAVID KERSHENOBICH STALNIKOWITZ Gallegos-Orozco J.F. et al.	LIVER INTERNATIONAL	2005
129	Differential modulation of interleukin 8 by interleukin 4 and interleukin 10 in HepG2 cells treated with acetaldehyde	DAVID KERSHENOBICH STALNIKOWITZ Gómez-Quiroz L.E. Paris R. et al.	LIVER INTERNATIONAL	2005
130	Matching Strategies for Genetic Association Studies in Structured Populations	DAVID KERSHENOBICH STALNIKOWITZ Hinds D.A. Stokowski R.P. et al.	AMERICAN JOURNAL OF HUMAN GENETICS	2004
131	Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-Week interim results of a pilot study	DAVID KERSHENOBICH STALNIKOWITZ Poo J.L. Sánchez-Avila F. et al.	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY	2004
132	Liver fibrosis and cirrhosis: are they reversible? [Fibrosis y cirrosis hepática: son reversibles?]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	2004
133	A vision of future treatment of liver diseases [Visión al futuro sobre el tratamiento de las enfermedades hepáticas.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	2004
134	Liver fibrosis and inflammation. A review.	DAVID KERSHENOBICH STALNIKOWITZ Weissbrod A.B.	Annals Of Hepatology	2003
135	Molecular biology in gastroenterology [Biología molecular en gastroenterología]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2003
136	Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin	ESPERANZA GABRIELA GUTIERREZ REYES DAVID KERSHENOBICH STALNIKOWITZ Gallegos-Orozco J.F. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2003
137	Interleukin 8 response and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde or lipopolysaccharide	DAVID KERSHENOBICH STALNIKOWITZ Gómez-Quiroz L. Bucio L. et al.	HEPATOLOGY RESEARCH	2003

DAVID KERSHENOBICH STALNIKOWITZ

138	Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents. [Comparación de dos esquemas diferentes de vacunación contra hepatitis A y B en niños y adolescentes mexicanos.]	DAVID KERSHENOBICH STALNIKOWITZ González-Huezo M.S. Sánchez-Avila F. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	2003
139	Amebic liver abscess.	ALDO TORRE DELGADILLO DAVID KERSHENOBICH STALNIKOWITZ	Annals Of Hepatology	2002
140	Mechanisms and cofactors of hepatitis C fibrosis [Mecanismos y cofactores de la fibrosis en la hepatitis C.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	2002
141	Trefoil factor 1 (TFF1/pS2) deficiency activates the unfolded protein response	DAVID KERSHENOBICH STALNIKOWITZ Torres L.-F. Karam S.M. et al.	MOLECULAR MEDICINE	2002
142	Emerging concepts in inflammation and fibrosis	GUILLERMO BENITO ROBLES DIAZ DAVID KERSHENOBICH STALNIKOWITZ Gutiérrez-Ruiz Ma.C.	Archives Of Medical Research	2002
143	School-based hepatitis B immunization program in adolescents	DAVID KERSHENOBICH STALNIKOWITZ JORGE GONZALEZ TEYSSIER Concepción Gutierrez-Ruiz M. et al.	JOURNAL OF ADOLESCENT HEALTH	2002
144	Pentoxifylline diminished acetaldehyde-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression	DAVID KERSHENOBICH STALNIKOWITZ Hernández E. Correa A. et al.	PHARMACOLOGICAL RESEARCH	2002
145	Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture	DAVID KERSHENOBICH STALNIKOWITZ Gutiérrez-Ruiz M.C. Bucio L. et al.	PHARMACOLOGICAL RESEARCH	2001
146	Viral dynamics in hepatitis C	DAVID KERSHENOBICH STALNIKOWITZ Henonin C.H.	ISRAEL MEDICAL ASSOCIATION JOURNAL	2001
147	Expression of urokinase-type plasminogen activator in an experimental model of hepatocarcinoma	ROGELIO HERNANDEZ PANDO DAVID KERSHENOBICH STALNIKOWITZ Nieto-Rodríguez A. et al.	Toxicology	2001
148	Cytokine response and oxidative stress produced by ethanol, acetaldehyde and endotoxin treatment in HepG2 cells.	DAVID KERSHENOBICH STALNIKOWITZ Gutierrez-Ruiz M.C. Gomez Quiroz L.E. et al.	ISRAEL MEDICAL ASSOCIATION JOURNAL	2001
149	Effect of endotoxin pretreatment on hepatic stellate cell response to ethanol and acetaldehyde	DAVID KERSHENOBICH STALNIKOWITZ Quiroz S.C. Bucio L. et al.	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY	2001

DAVID KERSHENOBICH STALNIKOWITZ

150	Hepatic fibrosis [Fibrosis hepática]	DAVID KERSHENOBICH STALNIKOWITZ Gutiérrez-Ruiz Ma.C.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	2001
151	Cytokines, growth factors, and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde, and LPS	DAVID KERSHENOBICH STALNIKOWITZ Gutiérrez-Ruiz Ma.C. Quiroz S.C. et al.	Toxicology	1999
152	Open formulary proposal for a managed care program in Mexico [Propuesta de un formulario abierto para un programa de atención médica dirigida en México]	RUBEN BURGOS VARGAS DAVID KERSHENOBICH STALNIKOWITZ ALBERTO LIFSHITZ Y GUINZBERG et al.	SALUD PUBLICA DE MEXICO	1999
153	Allelic association study between collagen type I (COL1A1 and COL1A2) polymorphisms and alcohol liver disease [Estudio de la asociación alelica entre los polimorfismos de los genes de colágeno tipo I (COL1A1 y COL1A2) y daño hepático de tipo I]	JOSE HUMBERTO NICOLINI SANCHEZ DAVID KERSHENOBICH STALNIKOWITZ Cruz C. et al.	SALUD MENTAL	1998
154	MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis	DAVID KERSHENOBICH STALNIKOWITZ Vázquez-García M.N. Aláez C. et al.	JOURNAL OF HEPATOLOGY	1998
155	Homenaje al doctor Salvador Zubirán (1898-1998).	DAVID KERSHENOBICH STALNIKOWITZ MANUEL CARDENAS LOAEZA Guevara-González L. et al.	GACETA MEDICA DE MEXICO	1998
156	Effect of the menstrual cycle in ethanol pharmacokinetics	JUAN RAMON DE LA FUENTE RAMIREZ MARTE LORENZANA JIMENEZ DAVID KERSHENOBICH STALNIKOWITZ et al.	JOURNAL OF APPLIED TOXICOLOGY	1998
157	Mexican consensus on Helicobacter pylori [Consenso Mexicano sobre Helicobacter pylori]	DAVID KERSHENOBICH STALNIKOWITZ Violante M.D. Díaz G.R. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1997
158	Antioxidants and human disease: A general introduction	DAVID KERSHENOBICH STALNIKOWITZ Halliwell B. Zentella A. et al.	NUTRITION REVIEWS	1997
159	Helicobacter pylori infection among patients with alcoholic and nonalcoholic cirrhosis	MAX JULIO SCHMULSON WASSERMAN DAVID KERSHENOBICH STALNIKOWITZ De Leon G. et al.	Helicobacter	1997
160	Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients	DAVID KERSHENOBICH STALNIKOWITZ Diliz H.S. Olivera M.A. et al.	TRANSPLANTATION PROCEEDINGS	1996

DAVID KERSHENOBICH STALNIKOWITZ

161	Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex	DAVID KERSHENOBICH STALNIKOWITZ Moteki S. Leung P.S.C. et al.	Hepatology	1996
162	The Cullen sign [Signo de Cullen.]	DAVID KERSHENOBICH STALNIKOWITZ Carmona R. Márquez-Díaz F.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1996
163	Primary biliary cirrhosis: clinical features and survival of a Mexican population [Cirrosis biliar primaria: características clínicas y supervivencia en la población Mexicana.]	DAVID KERSHENOBICH STALNIKOWITZ Morán S. Rodríguez-Leal G. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1996
164	Hepatitis A: is universal vaccination justified in Mexico? [Hepatitis A: se justifica la vacunación universal en México?]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1996
165	Liver fibrosis [Fibrosis hepática.]	DAVID KERSHENOBICH STALNIKOWITZ Taba Shiwa S. Garibay-Nieto N. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1996
166	Hazardous alcohol consumption among Mexican inpatients. A multicenter study	JUAN RAMON DE LA FUENTE RAMIREZ DAVID KERSHENOBICH STALNIKOWITZ Guevara-Arnal L. et al.	AM J ADDICTION	1995
167	Experience with primary biliary cirrhosis in Mexico [Experiencia en México con cirrosis biliar primaria.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1995
168	Advances in liver cirrhosis [Los avances en cirrosis hepática.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1995
169	Viral hepatitis and alcohol: a synergistic relationship [Hepatitis viral y alcohol: un sinergismo.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1995
170	Hepatitis B and liver cancer [Hepatitis B y cáncer de hígado.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1995

DAVID KERSHENOBICH STALNIKOWITZ

171	The dopamine d2 receptor gene TaqI al polymorphism and alcoholism in a Mexican population	JUAN RAMON DE LA FUENTE RAMIREZ DAVID KERSHENOBICH STALNIKOWITZ JOSE HUMBERTO NICOLINI SANCHEZ et al.	Archives Of Medical Research	1995
172	Non-alcoholic fatty liver: 10 years' experience at the Insituto Nacional de la Nutrición Salvador Zubirán [Esteatohepatitis no alcohólica: Experiencia de 10 años en el Instituto Nacional de la Nutrición Salvador Zubirán.]	DAVID KERSHENOBICH STALNIKOWITZ MISAEEL URIBE ESQUIVEL de la Mora G. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1994
173	Alcoholism markers [Marcadores de alcoholismo.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1994
174	Alcohol metabolism in healthy subjects	DAVID KERSHENOBICH STALNIKOWITZ JUAN RAMON DE LA FUENTE RAMIREZ Haddad L. et al.	Gastroenterology	1993
175	Prevalence of antinuclear antibodies in primary biliary cirrhosis, with negative antimitochondrial antibodies [Prevalencia de anticuerpos antinucleares en cirrosis biliar primaria, con anticuerpos antimitocondriales negativos.]	MISAEEL URIBE ESQUIVEL DAVID KERSHENOBICH STALNIKOWITZ Antonio Olivera M. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1993
176	Diarrhea as clinical expression of gastrinoma. A case report [Diarrea como expresión clínica de gastrinoma. Informe de un caso.]	DAVID KERSHENOBICH STALNIKOWITZ Meléndez N. Almazán J. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1993
177	Clinical characteristics and endoscopic-histologic correlation in patients with chronic non-specific ulcerative colitis [Características clínicas y correlación endoscópico-histológica en pacientes con colitis ulcerosa crónica inespecí	DAVID KERSHENOBICH STALNIKOWITZ Sánchez A. Zapata L. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1993
178	Pseudomembranous enteritis: Rediscovery of a previously well-described entity?	DAVID KERSHENOBICH STALNIKOWITZ Wiesen S. Gregg P.A. et al.	AMERICAN JOURNAL OF GASTROENTEROLOGY	1992

DAVID KERSHENOBICH STALNIKOWITZ

179	Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis	DAVID KERSHENOBICH STALNIKOWITZ Collawn C. Rubin P. et al.	AMERICAN JOURNAL OF GASTROENTEROLOGY	1992
180	Semiquantitative histologic evaluation of the liver in patients after liver transplantation	ROGELIO HERNANDEZ PANDO DAVID KERSHENOBICH STALNIKOWITZ MISAEEL URIBE ESQUIVEL et al.	TRANSPLANTATION PROCEEDINGS	1992
181	Liver transplantation in Mexico. Report of the first successful case [Trasplante de hígado en México. Informe del primer caso exitoso.]	DAVID KERSHENOBICH STALNIKOWITZ Diliz H. Orozco H. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1991
182	Hepatitis B in Latin America: Epidemiological patterns and eradication strategy	DAVID KERSHENOBICH STALNIKOWITZ Fay O.H. Da Costa Gayotto L.C. et al.	Vaccine	1990
183	Effect of colchicine on lymphocyte and monocyte function and its relation to fibroblast proliferation in primary biliary cirrhosis	DAVID KERSHENOBICH STALNIKOWITZ JORGE CARLOS ALCOCER VARELA Rojkind M. et al.	Hepatology	1990
184	Seroprevalence of viral markers of hepatitis B among health professionals. Multicenter study in Mexico [Seroprevalencia de marcadores virales de hepatitis B en profesionales de la salud. Estudio multicéntrico en México.]	DAVID KERSHENOBICH STALNIKOWITZ Hurtado R. Collawn C. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1990
185	Colchicine: rationale for its use in liver disease [Colchicina. Fundamentos para su uso en enfermedades hepáticas.]	DAVID KERSHENOBICH STALNIKOWITZ Borovoy J. Guevara R.L.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1990
186	Cytokines and the liver [Citocinas e hígado.]	DAVID KERSHENOBICH STALNIKOWITZ Borovoy J. Guevara L. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1990
187	Colchicine treatment of cirrhosis: answers.	DAVID KERSHENOBICH STALNIKOWITZ RUY ALONSO PEREZ TAMAYO Vargas F. et al.	Hepatology	1989
188	Colchicine in the treatment of cirrhosis	DAVID KERSHENOBICH STALNIKOWITZ RUY ALONSO PEREZ TAMAYO Fuller R.K. et al.	NEW ENGLAND JOURNAL OF MEDICINE	1988

DAVID KERSHENOBICH STALNIKOWITZ

189	Colchicine in the treatment of cirrhosis of the liver	DAVID KERSHENOBICH STALNIKOWITZ RUY ALONSO PEREZ TAMAYO Vargas F. et al.	NEW ENGLAND JOURNAL OF MEDICINE	1988
190	Alcoholic hepatitis [Hepatitis alcohólica.]	DAVID KERSHENOBICH STALNIKOWITZ Martín-Abreu L. Guevara L. et al.	GACETA MEDICA DE MEXICO	1987
191	Low and normal protein diets in chronic uremia: nitrogen and potassium balances and albumin and IgG turnover.	DAVID KERSHENOBICH STALNIKOWITZ Peña J.C. Domínguez M. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1986
192	Antiinflammatory and antifibrogenic activities of colchicine: treatment of liver cirrhosis.	DAVID KERSHENOBICH STALNIKOWITZ Rojkind M. Mourelle M.	Progress in clinical and biological research	1984
193	Diagnostic procedures for liver fibrosis.	DAVID KERSHENOBICH STALNIKOWITZ Rojkind M.	Laboratory And Research Methods In Biology And Medicine	1983
194	Early detection of alcoholism in a hospital population (author's transl) [Detección precoz de alcoholismo en una población hospitalaria.]	JUAN RAMON DE LA FUENTE RAMIREZ DAVID KERSHENOBICH STALNIKOWITZ Gutiérrez L.M. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1982
195	Alcohol and the liver [Alcohol e hígado.]	DAVID KERSHENOBICH STALNIKOWITZ Orillac J.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1982
196	Pathophysiology and treatment of fibrosis in liver cirrhosis [FISIOPATOLOGIA Y TRATAMIENTO DE LA FIBROSIS EN LA CIRROSIS HEPATICA]	DAVID KERSHENOBICH STALNIKOWITZ Rojkind M.	GASTROENTEROLOGIA Y HEPATOLOGIA	1982
197	Relationship between blood lactic acid and serum proline in alcoholic liver cirrhosis	DAVID KERSHENOBICH STALNIKOWITZ García-Tsao G. Saldana S.A. et al.	Gastroenterology	1981
198	Hepatic fibrosis	DAVID KERSHENOBICH STALNIKOWITZ Rojkind M.	Clinics In Gastroenterology	1981

DAVID KERSHENOBICH STALNIKOWITZ

199	Cholangitis. Study of 240 patients (author's transl) [Estudio comparativo de 240 casos con colangitis.]	DAVID KERSHENOBICH STALNIKOWITZ Alanís J.A. Fainsilber Z. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1980
200	Further evidence for the use of colchicine in the treatment of liver cirrhosis	DAVID KERSHENOBICH STALNIKOWITZ RUY ALONSO PEREZ TAMAYO Garcia-Tsao G. et al.	Gastroenterology	1980
201	Colchicine treatment in advanced chronic active liver disease (CALD)	DAVID KERSHENOBICH STALNIKOWITZ RUY ALONSO PEREZ TAMAYO Garcia Tsao G. et al.	Gastroenterology	1980
202	Reply	DAVID KERSHENOBICH STALNIKOWITZ Rojkind, M.	Gastroenterology	1980
203	Treatment of cirrhosis with colchicine. A double-blind randomized trial	DAVID KERSHENOBICH STALNIKOWITZ MISAEL URIBE ESQUIVEL RUY ALONSO PEREZ TAMAYO et al.	Gastroenterology	1979
204	Acute alcoholic hepatitis: clinical, biochemical and liver scintiscanning correlation in assessing prognosis.	MISAEL URIBE ESQUIVEL DAVID KERSHENOBICH STALNIKOWITZ Nieto L. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1979
205	Colchicine, serum albumin, and alkaline phosphatase	DAVID KERSHENOBICH STALNIKOWITZ MISAEL URIBE ESQUIVEL RUY ALONSO PEREZ TAMAYO et al.	ANNALS OF INTERNAL MEDICINE	1978
206	Endotoxins and liver [Endotoxinas e hígado.]	DAVID KERSHENOBICH STALNIKOWITZ Antonio Alanís J. Fe Bornstein M. et al.	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1978
207	Epidemiological aspects of alcoholic liver cirrhosis in Mexico (author's transl) [Consieraciones sobre la epidemiología de la cirrósisis hepática alcohólica en México.]	DAVID KERSHENOBICH STALNIKOWITZ Dajer F. Guevara L. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1978
208	Hepatic fibrosis.	DAVID KERSHENOBICH STALNIKOWITZ Rojkind M.	Progress In Liver Diseases	1976
209	Production of hydrochloric acid, mucus and enzymes [Producción de ácido clorhídrico, moco y enzimas.]	DAVID KERSHENOBICH STALNIKOWITZ	REVISTA DE GASTROENTEROLOGIA DE MEXICO	1976

DAVID KERSHENOBICH STALNIKOWITZ

210	Treatment of cirrhosis with colchicine: a randomized trial	DAVID KERSHENOBICH STALNIKOWITZ MISAEEL URIBE ESQUIVEL Suarez G.I. et al.	Gastroenterology	1976
211	Effect of colchicine on collagen, albumin and transferrin synthesis by cirrhotic rat liver slices	DAVID KERSHENOBICH STALNIKOWITZ Rojkind M.	Bba Section Nucleic Acids And Protein Synthesis	1975
212	Primary malignant neoplasms of the duodenum (author's transl) [Tumores malignos primarios del duodeno]	DAVID KERSHENOBICH STALNIKOWITZ Quiroz F. Guevara L. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1975
213	Serum free proline and free hydroxyproline in patients with chronic liver disease	DAVID KERSHENOBICH STALNIKOWITZ Mata J.M. Villarreal E. et al.	Gastroenterology	1975
214	Metabolism of immunoglobulins [Metabolismo de las inmunoglobulinas]	DAVID KERSHENOBICH STALNIKOWITZ	GACETA MEDICA DE MEXICO	1974
215	TREATMENT OF SCLERODERMA	DAVID KERSHENOBICH STALNIKOWITZ Alarcón-Segovia D. IBÁÑEZ G. et al.	Lancet	1974
216	Effects of inflammation on iron and transferrin metabolism	DAVID KERSHENOBICH STALNIKOWITZ O'Shea M.J. Tavill A.S.	BRITISH JOURNAL OF HAEMATOLOGY	1973
217	Effect of the administration of l-azetidine-2-carboxylic acid on albumin and transferrin biosynthesis by liver slices of rats treated with carbon tetrachloride	DAVID KERSHENOBICH STALNIKOWITZ Rojkind M.	Bba Section Nucleic Acids And Protein Synthesis	1973
218	COLCHICINE AND THE TREATMENT OF LIVER CIRRHOSIS	MISAEEL URIBE ESQUIVEL DAVID KERSHENOBICH STALNIKOWITZ Rojkind M.	Lancet	1973
219	Active chronic liver diseases. Classification and diagnostic criteria [Hepatopatías crónicas activas. Clasificación y criterios diagnósticos.]	DAVID KERSHENOBICH STALNIKOWITZ Alarcón-Segovia D. Velázquez F. et al.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1972
220	Effects of inflammation on iron and transferrin metabolism.	DAVID KERSHENOBICH STALNIKOWITZ O'Shea M.J. Tavill A.S.	BRITISH JOURNAL OF HAEMATOLOGY	1971

DAVID KERSHENOBICH STALNIKOWITZ

221	Antacid added to skim milk in the treatment of duodenal ulcer [Antiácido adicionado a leche semidescremada en el tratamineto de la úlcera duodenal.]	DAVID KERSHENOBICH STALNIKOWITZ Jesús Villalobos J. Ramírez Mata M.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1970
222	The relationship between the free pool of proline and collagen content in human liver cirrhosis.	DAVID KERSHENOBICH STALNIKOWITZ Fierro F.J. Rojkind M.	JOURNAL OF CLINICAL INVESTIGATION	1970
223	Sleep paralysis [La parálisis del sueño.]	DAVID KERSHENOBICH STALNIKOWITZ Hernández Peniche J.	REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION	1969

DAVID KERSHENOBICH STALNIKOWITZ

LIBROS Y CAPITULOS CON ISBN

Obras con registro ISBN



#	Título	Autores	Alcance	Año	ISBN
1	COVID-19: Medidas, adaptación y aprendizaje	JESUS CARLOS BRIONES GARDUÑO MARIO JACOBO CRUZ MONTTOYA ROBERTO GONZALEZ GONZALEZ et al.	Libro Completo	2023	9786073083959
2	COVID-19: Medidas, adaptación y aprendizaje	JESUS CARLOS BRIONES GARDUÑO MARIO JACOBO CRUZ MONTTOYA ROBERTO GONZALEZ GONZALEZ et al.	Libro Completo	2023	9786073084963
3	Enfermedades hepáticas en la mujer. Abordaje y tratamiento	MISAEEL URIBE ESQUIVEL MAYRA VIRGINIA RAMOS GOMEZ ALFREDO ADOLFO REZA ALBARRAN et al.	Libro Completo	2020	9786079618889
4	Medicina de precisión en hepatología	DAVID KERSHENOBICH STALNIKOWITZ JOSE LUIS PEREZ HERNANDEZ SOPHIA EUGENIA MARTINEZ VAZQUEZ et al.	Libro Completo	2020	9786079618896

DAVID KERSHENOBICH STALNIKOWITZ

5	IV Curso para Medicos de Primer Contacto	JUDITH FLORES CALDERON MAYRA VIRGINIA RAMOS GOMEZ JUAN MIGUEL ABDO FRANCIS et al.	Libro Completo	2019	9786079618841
6	Is Human Cirrhosis a Reversible Disease?	DAVID KERSHENOBICH STALNIKOWITZ Gutiérrez-Reyes D.G.	Capítulo de un Libro	2017	9780128043219
7	Envejecimiento y salud: Una propuesta para un plan de acción.	DAVID KERSHENOBICH STALNIKOWITZ	Libro Completo	2015	9786074605129
8	Hacia dónde va la ciencia en México. Salud Mental y Adicciones	DAVID KERSHENOBICH STALNIKOWITZ SHOSHANA BERENZON GORN	Libro Completo	2015	9786078273171
9	Hacia dónde va la Ciencia en México. Salud Mental y Adicciones	DAVID KERSHENOBICH STALNIKOWITZ SHOSHANA BERENZON GORN	Libro Completo	2015	9786079138226
10	Hepatología. Tópicos Innovadores	DAVID KERSHENOBICH STALNIKOWITZ ALDO TORRE DELGADILLO	Libro Completo	2013	9786077797081
11	Envejecimiento y salud: una propuesta para un plan de acción	MARIA DE LA LUZ MARTINEZ MALDONADO DAVID KERSHENOBICH STALNIKOWITZ	Libro Completo	2013	9786070243721
12	Envejecimiento y salud: una propuesta para un plan de acción	DAVID KERSHENOBICH STALNIKOWITZ	Libro Completo	2013	9786070246739
13	Políticas de salud para la prevención de las enfermedades crónicas no transmisibles en México	RICARDO POZAS HORCASITAS DAVID KERSHENOBICH STALNIKOWITZ	Libro Completo	2013	9786079367008
14	Liver protozoa	DAVID KERSHENOBICH STALNIKOWITZ GUILLERMO BENITO ROBLES DIAZ Francis J.M.A.	Capítulo de un Libro	2012	1405191821
15	Especialidades médicas	PELAYO VILAR PUIG DAVID KERSHENOBICH STALNIKOWITZ	Libro Completo	2012	978607804596 9

DAVID KERSHENOBICH STALNIKOWITZ

16	Gastroenterología	EDUARDO PEREZ TORRES FERNANDO BERNAL SAHAGUN DAVID KERSHENOBICH STALNIKOWITZ	Libro Completo	2011	9786071506153
17	Amoebic and Pyogenic Liver Abscesses	DAVID KERSHENOBICH STALNIKOWITZ Olivera-Martínez M.A.	Capítulo de un Libro	2011	0470654686
18	Cuaderno del Seminario de Medicina y Salud	DAVID KERSHENOBICH STALNIKOWITZ OCTAVIO RIVERO SERRANO	Libro Completo	2009	978607020885 0
19	Medicina y Salud-Enfermedades emergentes	DAVID KERSHENOBICH STALNIKOWITZ	Libro Completo	2009	9786074431049
2 0	Protozoal Infections Affecting the Liver	DAVID KERSHENOBICH STALNIKOWITZ GUILLERMO BENITO ROBLES DIAZ Abdo J.M. et al.	Capítulo de un Libro	2008	9781405127417



Sistema Integral de Información Académica
Coordinación de Planeación, Evaluación y
Simplificación de la Gestión Institucional
Reporte individual



DAVID KERSHENOBICH STALNIKOWITZ

PARTICIPACIÓN EN PROYECTOS

No se encuentran registros en la base de datos de SISEPRO asociados a:

DAVID KERSHENOBICH STALNIKOWITZ



Sistema Integral de Información Académica
Coordinación de Planeación, Evaluación y
Simplificación de la Gestión Institucional
Reporte individual



DAVID KERSHENOBICH STALNIKOWITZ

PARTICIPACIÓN EN TESIS


No se encuentran registros en la base de datos de TESIUNAM asociados a:

DAVID KERSHENOBICH STALNIKOWITZ

DAVID KERSHENOBICH STALNIKOWITZ

DOCENCIA IMPARTIDA

Histórico de docencia



#	Nivel titulación	Asignatura	Entidad	Alumnos	Semestre
1	Maestría	TRABAJO DE INVESTIGACION IV	Facultad de Medicina	1	2015-1
2	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Medicina	1	2014-2
3	Maestría	TRABAJO DE INVESTIGACION IV	Facultad de Medicina	1	2014-1
4	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Medicina	1	2014-1
5	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Medicina	1	2013-2
6	Maestría	TRABAJO DE INVESTIGACION I	Facultad de Medicina	1	2013-2
7	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Medicina	1	2013-1
8	Maestría	TRABAJO DE INVESTIGACION IV	Facultad de Medicina	1	2013-1
9	Maestría	TRABAJO DE INVESTIGACION III	Facultad de Medicina	1	2012-2
10	Maestría	COLOQUIO DE INVESTIGACION III	Facultad de Medicina	12	2012-2
11	Maestría	COLOQUIO DE INVESTIGACION I	Facultad de Medicina	18	2012-2
12	Maestría	COLOQUIO DE INVESTIGACION II	Facultad de Medicina	14	2012-1
13	Maestría	TRABAJO DE INVESTIGACION II	Facultad de Medicina	2	2012-1
14	Maestría	TRABAJO DE INVESTIGACION I	Facultad de Medicina	1	2011-2
15	Maestría	COLOQUIO DE INVESTIGACION I	Facultad de Medicina	14	2011-2
16	Licenciatura	UNIDAD TEORICA 10	Facultad de Medicina	4	2009-1



Sistema Integral de Información Académica
Coordinación de Planeación, Evaluación y
Simplificación de la Gestión Institucional
Reporte individual



DAVID KERSHENOBICH STALNIKOWITZ

PATENTES

#	Título	Inventores	Sección	Año
1	ARREGLO MÚLTIPLE DE ANTICUERPOS ESPECÍFICOS PARA EL PRONÓSTICO, DETECCIÓN Y VIGILANCIA DEL PROCESO FIBROGÉNICO.	DAVID KERSHENOBICH STALNIKOWITZ, ESPERANZA GABRIELA GUTIERREZ REYES,	PHYSICS	2018

DAVID KERSHENOBICH STALNIKOWITZ

FUENTES DE INFORMACIÓN

Internos

#	Información	Fuente	Sistema	Periodo
1	Grupos ordinarios y resumen de historias académicas	DGAE	SIAE	2008-2025
2	Nombramientos, datos generales, estímulos, premios y reconocimientos	DGAPA	RUPA	2008-2025
3	Producción Académica	CH	Humanindex	2008-2021
4	Producción Académica	CIC	SCIC	2000-2017
5	Proyectos	DGPO	SISEPRO	2018-2022
6	Tesis	DGB	TESIUNAM	2008-2025
7	Tutorías en Posgrado	CGEP	SIIPosgrado	2008-2021

Externos

#	Información	Fuente	Sistema	Periodo
8	Documentos Indexados	Elsevier	Scopus	2008-2025
9	Documentos Indexados	Thomson Reuters	WoS	2008-2025
10	Obras con registro ISBN	INDAUTOR	Agencia ISBN	2008-2025
11	Patentes	IMPI	SIGA	2008-2024